Acquired resistance gene enables deadly bacteria to withstand both antibiotics and hospital disinfectants
A Monash University study published in Nature Communications reveals that Clostridioides difficile bacteria have acquired a gene that allows their dormant spores to resist both antibiotics and hospital-grade cleaning products. This dangerous adaptation represents an unexpected evolutionary pathway where antibiotic resistance provides protection against disinfectants as well, creating a compounded threat in hospital settings where the bacterium commonly causes severe infections. The finding underscores how antibiotic resistance drives bacteria to develop sophisticated survival mechanisms with potentially catastrophic public health implications.
Clostridioides difficile is a spore-forming bacterium frequently encountered in hospital environments, where it causes severe gastrointestinal infections in vulnerable patients. The bacterium's survival strategy relies on dormant spores that function similarly to seeds, remaining inactive until conditions in the human digestive system become favorable for activation and transmission. When the bacterium acquires an antibiotic resistance gene, it alters the protein composition used to construct these protective spores, fundamentally changing their structural composition and enhancing their durability against both pharmaceutical interventions and chemical disinfectants used in clinical settings.
This discovery could significantly affect infection control protocols in healthcare facilities, as standard disinfection procedures may prove less effective against resistant C. difficile strains. Vulnerable populations—particularly hospitalized patients with compromised immune systems—may face elevated risk from harder-to-treat infections. The findings could prompt healthcare systems to reconsider cleaning practices and infection prevention strategies. Additionally, the research may influence how pharmaceutical companies approach antimicrobial development, potentially redirecting focus toward addressing spore-formation mechanisms rather than solely targeting active bacterial cells.